CN111956796B - 增强对艾美球虫的免疫应答或限制艾美球虫感染的组合物和方法 - Google Patents

增强对艾美球虫的免疫应答或限制艾美球虫感染的组合物和方法 Download PDF

Info

Publication number
CN111956796B
CN111956796B CN202010782256.8A CN202010782256A CN111956796B CN 111956796 B CN111956796 B CN 111956796B CN 202010782256 A CN202010782256 A CN 202010782256A CN 111956796 B CN111956796 B CN 111956796B
Authority
CN
China
Prior art keywords
lys
glu
ala
gly
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010782256.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN111956796A (zh
Inventor
J·R·巴尔塔
L·贝里曼
L·比耶尔克
B·哈吉斯
S·施瓦拉迈亚
O·B·福克纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
University of Arkansas at Little Rock
Original Assignee
Texas A&M University System
University of Arkansas at Little Rock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System, University of Arkansas at Little Rock filed Critical Texas A&M University System
Priority to CN202010782256.8A priority Critical patent/CN111956796B/zh
Publication of CN111956796A publication Critical patent/CN111956796A/zh
Application granted granted Critical
Publication of CN111956796B publication Critical patent/CN111956796B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202010782256.8A 2013-02-14 2014-02-14 增强对艾美球虫的免疫应答或限制艾美球虫感染的组合物和方法 Active CN111956796B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010782256.8A CN111956796B (zh) 2013-02-14 2014-02-14 增强对艾美球虫的免疫应答或限制艾美球虫感染的组合物和方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361764681P 2013-02-14 2013-02-14
US61/764,681 2013-02-14
PCT/US2014/016359 WO2014127185A1 (en) 2013-02-14 2014-02-14 Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
CN201480021011.6A CN105142665A (zh) 2013-02-14 2014-02-14 增强对艾美球虫的免疫应答或限制艾美球虫感染的组合物和方法
CN202010782256.8A CN111956796B (zh) 2013-02-14 2014-02-14 增强对艾美球虫的免疫应答或限制艾美球虫感染的组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480021011.6A Division CN105142665A (zh) 2013-02-14 2014-02-14 增强对艾美球虫的免疫应答或限制艾美球虫感染的组合物和方法

Publications (2)

Publication Number Publication Date
CN111956796A CN111956796A (zh) 2020-11-20
CN111956796B true CN111956796B (zh) 2024-09-13

Family

ID=51354559

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010782256.8A Active CN111956796B (zh) 2013-02-14 2014-02-14 增强对艾美球虫的免疫应答或限制艾美球虫感染的组合物和方法
CN201480021011.6A Pending CN105142665A (zh) 2013-02-14 2014-02-14 增强对艾美球虫的免疫应答或限制艾美球虫感染的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480021011.6A Pending CN105142665A (zh) 2013-02-14 2014-02-14 增强对艾美球虫的免疫应答或限制艾美球虫感染的组合物和方法

Country Status (23)

Country Link
US (6) US9603915B2 (https=)
EP (2) EP2956165B1 (https=)
JP (2) JP6532407B2 (https=)
KR (1) KR102228324B1 (https=)
CN (2) CN111956796B (https=)
AR (1) AR094791A1 (https=)
AU (1) AU2014216246B2 (https=)
BR (1) BR112015019283B1 (https=)
CA (1) CA2900644C (https=)
CL (1) CL2015002273A1 (https=)
DK (1) DK2956165T3 (https=)
EA (1) EA030929B1 (https=)
ES (2) ES2968398T3 (https=)
HU (1) HUE047484T2 (https=)
MX (1) MX2015010555A (https=)
MY (2) MY173328A (https=)
NZ (1) NZ711019A (https=)
PH (1) PH12015501784A1 (https=)
PL (1) PL2956165T3 (https=)
PT (1) PT2956165T (https=)
SG (2) SG10202109925TA (https=)
WO (1) WO2014127185A1 (https=)
ZA (1) ZA201505638B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3097926T (pt) * 2007-11-01 2020-01-08 Univ Guelph Composições e métodos de potenciação das respostas imunitárias frente a eimeria
AR094791A1 (es) 2013-02-14 2015-08-26 Univ Arkansas Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
CN104940924B (zh) * 2015-05-29 2018-01-16 中国农业大学 一种球虫佐剂及其应用
KR102767638B1 (ko) * 2016-05-03 2025-02-20 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
CN106047914A (zh) * 2016-05-10 2016-10-26 吉林大学 一种用于预防猪弓形虫病的重组卡介苗及制备方法
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
WO2018226887A1 (en) 2017-06-07 2018-12-13 Spark Therapeutics, Inc. ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION
US12605239B2 (en) 2020-07-29 2026-04-21 North Carolina State University Enhancement of hydration and improvement in gut health through cloacal delivery of products
US11497801B2 (en) * 2021-02-19 2022-11-15 Sherryll Layton Compositions and methods of enhancing immune responses
CN115227810A (zh) * 2022-04-18 2022-10-25 福建农林大学 一种鸡抗巨型艾美耳球虫口服重组芽孢疫苗及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101969990A (zh) * 2007-11-01 2011-02-09 阿肯色大学评议会 增强针对艾美球虫属的免疫反应的组合物和方法
CN102811734A (zh) * 2010-01-21 2012-12-05 阿肯色大学评议会 增强免疫应答的疫苗载体和方法

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3415145B2 (ja) 1991-03-05 2003-06-09 ザ ウエルカム ファウンデーション リミテッド 弱毒化細菌における組換えタンパク質の発現
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
ES2198025T3 (es) 1991-10-25 2004-01-16 Immunex Corporation Anticuerpos contra cd40-l.
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
CA2143299A1 (en) 1992-09-04 1994-03-17 University Of Saskatchewan Novel bacterial vaccines using vaccine strains of pathogenic bacteria
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5565321A (en) 1993-01-22 1996-10-15 Immunex Corporation Detection of mutations in a CD40 ligand gene
WO1995014487A1 (en) 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide
ATE309267T1 (de) 1994-04-28 2005-11-15 Boehringer Ingelheim Pharma Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
ES2179187T3 (es) 1995-03-01 2003-01-16 Immunex Corp Oriteuba qye se yba a cd40 para estimular una respuesta inmune.
IL122174A (en) 1995-06-07 2004-07-25 Immunex Corp Dna encoding a cd40l mutein and a cd40l polypeptide encoded by said dna
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6969609B1 (en) 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
IL136731A0 (en) 1997-12-19 2001-06-14 Immunex Corp Method for reducing susceptibility to hiv infection
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
IT1299583B1 (it) 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
DE69939264D1 (de) 1998-09-04 2008-09-18 Emergent Product Dev Uk Ltd Attenuierte salmonella spi2 mutante als antigen-träger
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1067194A1 (en) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
JP2003508016A (ja) 1999-04-16 2003-03-04 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
US7803765B2 (en) 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
WO2001026608A2 (en) 1999-10-14 2001-04-19 Ledbetter Jeffrey A Dna vaccines encoding antigen linked to a domain that binds cd40
TR200401569T4 (tr) 1999-12-28 2004-07-21 Akzo Nobel N.V. Flagelin ya da flagelle'ya karşı antikorların oluşumuna sebep olmayan salmonelle aşısı
CA2399790C (en) 2000-02-02 2012-10-30 Ralph A. Tripp Cd40 ligand adjuvant for respiratory syncytial virus
DE60112413T2 (de) 2000-03-17 2006-06-01 Pharmacia & Upjohn Co. Llc, Kalamazoo Ssa inaktivierte salmonella impfstoffe
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
US20030165538A1 (en) 2000-06-26 2003-09-04 Maxygen Incorporated Methods and compositions for developing spore display systems for medicinal and industrial applications
AU2002221780A1 (en) 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
CN100447154C (zh) 2001-05-15 2008-12-31 费因斯坦医学研究学院 利用hmg片段作为抗炎症试剂
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7811816B2 (en) 2001-05-15 2010-10-12 Ortho-Mcneil Pharmaeutical, Inc. Isolated CD8 +T lymphocytes specifically cytotoxic for a disease causing target cell
ZA200400479B (en) 2001-07-06 2006-05-31 Abic Biolog Lab Teva Nucleic acids encoding recombinant 56 a 82 KDA antigens from gametocytes of Eimeria maxima and their use
CN100348608C (zh) 2001-07-06 2007-11-14 Abic特瓦生物实验室有限公司 编码重组的来源于巨型艾美球虫子孢子/裂殖子的250kDa抗原的核酸,和它们的应用
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
US7378089B2 (en) 2001-10-02 2008-05-27 The Board Of Trustees Of The Leland Stanford Junior University Gene therapy for the prevention of autoimmune disease
DE50212280D1 (de) 2001-12-19 2008-06-26 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
ES2309224T3 (es) 2001-12-21 2008-12-16 Immunex Corporation Polipeptidos recombinantes.
ATE421249T1 (de) 2002-02-13 2009-02-15 Immunology Lab Inc Zusammensetzungen und verfahren für die behandlung von mikroorganismen-infektionen
US6923958B2 (en) 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
CA2526895A1 (en) 2002-04-15 2003-11-27 Washington University Regulated attenuation of live vaccines to enhance cross protective immunogenicity
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US20060121047A1 (en) 2002-11-20 2006-06-08 Tracey Kevin J Use of hmgb polypetides for increasing immune responses
JP2006510619A (ja) 2002-11-20 2006-03-30 クリティカル セラピューティクス，インコーポレイテッド 抗炎症剤としてのｈｍｇｂ断片の使用
US20040141948A1 (en) 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
US20060014248A1 (en) 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050181994A1 (en) 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
EP1673389A2 (en) 2003-10-10 2006-06-28 Xencor Inc. Novel variants of cd40l protein
CA2548347A1 (en) 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
US8828957B2 (en) 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
US20080305120A1 (en) 2004-06-17 2008-12-11 Medimmune, Inc. Immunogenic Compositions Comprising Hmgb 1 Polypeptides
WO2006012373A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
CN101044160A (zh) * 2004-08-19 2007-09-26 蛋白质组系统知识产权有限公司 结核分支杆菌感染的诊断和治疗方法及所用试剂
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2006042177A2 (en) 2004-10-07 2006-04-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
WO2006130525A2 (en) 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
WO2007011606A2 (en) 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
AU2006301171B9 (en) 2005-10-07 2012-03-29 Proyecto De Biomedicina Cima, S.L. Immunostimulatory combination for the prophylactics and treatment of hepatitis C
EP1951862B1 (en) 2005-11-07 2013-07-24 MicroVAX, LLC Cd40 ligand fusion protein vaccine
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
US7829097B2 (en) 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
US8802419B2 (en) 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
PL2066339T3 (pl) 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
WO2008109825A2 (en) 2007-03-08 2008-09-12 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
CN101024076B (zh) 2007-03-29 2010-08-18 中国农业大学 球虫的新用途
WO2009059018A1 (en) 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
CN101234196A (zh) 2007-11-30 2008-08-06 吉林大学 球虫重组卡介苗及制备方法
PT2329266E (pt) 2008-09-11 2016-06-07 Pasteur Institut Monitorização e inibição da infecção pelo vírus da imunodeficiência humana mediante modulação do desencadeamento dependente de hmgb1 da replicação e persistência do vih-1
EP2355844A2 (en) 2008-11-13 2011-08-17 Intervet International BV Eimeria vaccine for turkeys
US20100150958A1 (en) 2008-12-15 2010-06-17 Vectogen Pty Ltd. Methods and Compositions for Use of a Coccidiosis Vaccine
JP2011072284A (ja) * 2009-10-01 2011-04-14 Mitsubishi Chemicals Corp 抗体の製造方法及びそれに用いる免疫原性組成物
MX350306B (es) 2010-06-09 2017-09-04 Univ Arkansas Vacuna y metodos para reducir una infeccion por campylobacter.
US20150297714A1 (en) 2012-10-29 2015-10-22 The Board Of Trustees Of The University Of Arkansas Novel mucosal adjuvants and delivery systems
AR094791A1 (es) 2013-02-14 2015-08-26 Univ Arkansas Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101969990A (zh) * 2007-11-01 2011-02-09 阿肯色大学评议会 增强针对艾美球虫属的免疫反应的组合物和方法
CN102811734A (zh) * 2010-01-21 2012-12-05 阿肯色大学评议会 增强免疫应答的疫苗载体和方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A spatially localized rhomboid protease cleaves cell surface adhesins essential for invasion by Toxoplasma;Fabien Brossier等;PNAS;第102卷(第11期);第4146页摘要、第4148页左栏倒数第1段、supporting information *
Toxoplasma gondii rhomboid protein 1 (TgROM1) is a potential vaccine candidate against toxoplasmosis;Jianhua Li等;Veterinary Parasitology;第184卷(第2期);第154页摘要，第155页右栏第2段 *

Also Published As

Publication number Publication date
JP2019073554A (ja) 2019-05-16
CA2900644C (en) 2023-03-14
ES2968398T3 (es) 2024-05-09
EP2956165B1 (en) 2019-09-11
MX2015010555A (es) 2015-09-28
US9884099B2 (en) 2018-02-06
MY173328A (en) 2020-01-16
JP2016513956A (ja) 2016-05-19
KR20150119110A (ko) 2015-10-23
EP3610887C0 (en) 2023-11-15
US20160000895A1 (en) 2016-01-07
BR112015019283A2 (pt) 2017-07-18
US20210008184A1 (en) 2021-01-14
EP2956165A1 (en) 2015-12-23
EA030929B1 (ru) 2018-10-31
AU2014216246A8 (en) 2015-11-19
NZ711019A (en) 2019-07-26
US20190298815A1 (en) 2019-10-03
AU2014216246A2 (en) 2015-10-01
DK2956165T3 (da) 2019-12-02
US20180169198A1 (en) 2018-06-21
ZA201505638B (en) 2023-05-31
PH12015501784B1 (en) 2015-12-07
SG11201506398SA (en) 2015-09-29
HK1218880A1 (en) 2017-03-17
US10792351B2 (en) 2020-10-06
US20220288175A1 (en) 2022-09-15
EP3610887A1 (en) 2020-02-19
JP6532407B2 (ja) 2019-06-19
PL2956165T3 (pl) 2020-04-30
US11904005B2 (en) 2024-02-20
CL2015002273A1 (es) 2015-12-04
EA201591488A1 (ru) 2016-01-29
US11364290B2 (en) 2022-06-21
ES2758759T3 (es) 2020-05-06
CN111956796A (zh) 2020-11-20
MY200497A (en) 2023-12-28
US9603915B2 (en) 2017-03-28
PT2956165T (pt) 2019-11-29
JP6874031B2 (ja) 2021-05-19
AR094791A1 (es) 2015-08-26
US10328137B2 (en) 2019-06-25
SG10202109925TA (en) 2021-10-28
PH12015501784A1 (en) 2015-12-07
KR102228324B1 (ko) 2021-03-15
BR112015019283B1 (pt) 2023-12-19
HUE047484T2 (hu) 2020-04-28
EP3610887B1 (en) 2023-11-15
US20170182136A1 (en) 2017-06-29
AU2014216246A1 (en) 2015-09-10
WO2014127185A1 (en) 2014-08-21
CN105142665A (zh) 2015-12-09
AU2014216246B2 (en) 2018-12-20
EP3610887B8 (en) 2024-01-24
EP2956165A4 (en) 2016-09-21
CA2900644A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
CN111956796B (zh) 增强对艾美球虫的免疫应答或限制艾美球虫感染的组合物和方法
KR102239207B1 (ko) 장내 병원균에 대한 면역 반응을 증진시키는 조성물 및 방법
US11382962B2 (en) Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
JP4573773B2 (ja) マラリア・ワクチン
Barta et al. Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
HK1218880B (en) Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant